Corneal collagen cross-linking for progressing keratoconus in paediatric patients: five year follow-up

Session Details

Session Title: Cross-Linking

Session Date/Time: Tuesday 25/09/2018 | 14:00-16:00

Paper Time: 14:24

Venue: Room A3, Podium 3

First Author: : D.Wajnsztajn Vamos ISRAEL

Co Author(s): :    B. Rosin   A. Solomon   S. Frenkel   D. Landau   J. Frucht-Pery        

Abstract Details

Purpose:

To report the 5 year-outcome of cross-linking (CXL) for progressing keratoconus (KC) in pediatric patients.

Setting:

Hadassah Medical Center – Hebrew University Hospital

Methods:

Retrospective review of files of patients ≤18yrs-old who had CXL for KC (August 2007 to August 2017) with minimal follow-up of 6 months. Main outcomes were best corrected visual acuity (BCVA in LogMAR) and maximum keratometry (Kmax). We used Dresden protocol with regular or hypotonic riboflavin (UV-X ™ Specifications, IROC, Zurich, Switzerland). Statistical analysis was performed by Wilcoxon Rank Sum Test (Matlab 2013b, The Mathworks Inc, Natick MA).

Results:

142 eyes (105 patients) with mean age 15.7±2.1yrs (10-18yrs) had CXL for KC. Pachymetry was 462±44.9μm (328-575μm). Kmax and BCVA changed at 48 months (n=32) from 55.9±6.2D to 51.9±4.7D (p=0.007) and from 0.34±0.16 to 0.25±0.23 (p=0.013) respectively and at 60 months (n=14) from 54±5.5D to 50.4±6.2D (p=0.023) and from 0.29±0.17 to 0.22±0.22 (p=0.024) respectively. At 48 months Kmax was better (>1D) or stable (±1D) in 100%. At 60 months Kmax increased >1D in 7.1%. One eye had microbial keratitis, 1 had sterile infiltrates and 4 had haze. One eye had re-treatment.

Conclusions:

CXL is efficient to stop progression of KC in pediatric patients.

Financial Disclosure:

-